Moody Aldrich Partners’s ArriVent BioPharma AVBP Stock Holding History

Moody Aldrich Partners’s Portfolio AVBP Stock Details AVBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.53M	Sell	44,044 -12,044	-21%	-$355K	0.27%	112
2026 Q1	$1.29M	Sell	56,088 -571	-1%	-$12.9K	0.23%	117
2025 Q4	$1.14M	Sell	56,659 -2,795	-5%	-$58.2K	0.21%	116
2025 Q3	$1.1M	Sell	59,454 -12,121	-17%	-$238K	0.21%	112
2025 Q2	$1.56M	Buy	+71,575	New	+$1.49M	0.3%	101

Other funds holding AVBP

Tema ETFs New York $3.09B AUM 72.72% 1-Year Est. Return

Ellsworth Advisors Hudson, Ohio $609M AUM 52.37% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

PSP Research Newtown Square, Pennsylvania $188M AUM

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

VCM

Versant Capital Management Phoenix, Arizona $1.12B AUM 34.21% 1-Year Est. Return

Torren Management San Diego, California $197M AUM

MPWT

MassMutual Private Wealth & Trust Windsor, Connecticut $3.87B AUM 24.64% 1-Year Est. Return

Moody Aldrich Partners's AVBP Position: Q2 2026 in Review

Moody Aldrich Partners reduced its ArriVent BioPharma (AVBP) stake by 21% in Q2 2026, selling an estimated $355K and leaving 44,044 shares worth $1.53M. The position accounts for 0.27% of the portfolio, ranked #112.

Moody Aldrich Partners first reported a position in AVBP in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.56M in Q2 2025. 10 funds tracked by Wall St. Rank hold AVBP as of Q2 2026.

Moody Aldrich Partners held 44,044 shares of ArriVent BioPharma worth $1.53M as of Q2 2026.
Moody Aldrich Partners sold 12,044 ArriVent BioPharma shares in Q2 2026, an estimated $355K.
ArriVent BioPharma made up 0.27% of Moody Aldrich Partners's portfolio in Q2 2026, its #112 holding.
Moody Aldrich Partners first reported a position in ArriVent BioPharma in Q2 2025 and has held it in 5 quarters since.
Moody Aldrich Partners's ArriVent BioPharma position peaked at $1.56M in Q2 2025.
10 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2026.

Based on Moody Aldrich Partners's 13F filing for Q2 2026, filed 15 Jul 2026.